Loading
2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Triple-negative | Early disease | Surgery and radiotherapy, with chemotherapy as for triple-negative disease of no special type; chemotherapy and radiotherapy were associated with better survival in the national database, and axillary dissection was not. Low-grade adenosquamous and fibromatosis-like forms are treated by surgery alone in the European working group's consensus. | 83 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Triple-negative | Advanced disease | As for metastatic triple-negative disease (pembrolizumab where PD-L1 positive, TROP2 ADCs); response to chemotherapy is poorer than in other triple-negative cancers. | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.